Ixazomib, lenalidomide, and dexamethasone is effective and well tolerated in multiply relapsed (≥2nd relapse) refractory myeloma: a multicenter real world UK experience

References

• Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer. 2018;124(20):4032–4043.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, San-Miguel J, Belch A, et al. Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX. Haematologica. 2018;103(12):2088–2096.
   PubMed Web of Science ®Google Scholar
• Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621–631.
   PubMed Web of Science ®Google Scholar
• Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142–152.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319–1331.
   PubMed Web of Science ®Google Scholar
• Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621–1634.
   PubMed Web of Science ®Google Scholar
• Bergin K, McQuilten Z, Moore E, et al. Myeloma in the real world: what is really happening? Clin Lymphoma Myeloma Leuk. 2017;17(3):133–144.e1.
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Real-world and clinical trial data in relapsed/refractory multiple myeloma (RRMM): evaluating treatment duration and comparing effectiveness and efficacy. Blood. 2017;130:3149.
   Web of Science ®Google Scholar
• Shah JJ, Abonour R, Gasparetto C, et al. Analysis of common eligibility criteria of randomized controlled trials in newly diagnosed multiple myeloma patients and extrapolating outcomes. Clin Lymphoma Myeloma Leuk. 2017;17(9):575–583.e2.
   PubMed Web of Science ®Google Scholar
• Makady A, de Boer A, Hillege H, et al. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017;20(7):858–865.
   PubMed Web of Science ®Google Scholar
• Armoiry X, Connock M, Tsertsvadze A, et al. Ixazomib for relapsed or refractory multiple myeloma: review from an evidence review group on a NICE single technology appraisal. Pharmacoeconomics. 2018;36(9):1073–1079.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Therneau TM, Gertz MA, et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc. 2004;79(7):867–874.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26(1):149–157.
   PubMed Web of Science ®Google Scholar
• Pawlyn C, Morgan GJ. Evolutionary biology of high-risk multiple myeloma. Nat Rev Cancer. 2017;17(9):543–556.
   PubMed Web of Science ®Google Scholar
• Varga G, Nagy Z, Demeter J, et al. Real world efficacy and safety results of ixazomib lenalidomide and dexamethasone combination in relapsed/refractory multiple myeloma: data collected from the Hungarian Ixazomib Named Patient Program. Pathol Oncol Res. 2019;25:5–10.
   Web of Science ®Google Scholar
• Terpos E, Maouche N, Minarik J. “Real World” data on the efficacy and safety of ixazomib in combination with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: a study of the Greek Myeloma Study Group [Internet]; 2017; [cited 2018 May 14]. Available from: https://learningcenter.ehaweb.org/eha/2017/22nd/18; https://learningcenter.ehaweb.org/eha/2017/22nd/181025/evangelos.terpos.real.world.data.on.the.efficacy.and.safety.of.ixazomib.in.html
   Google Scholar
• Ziff M, Cheesman S, Kyriakou C. Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma; 2020. Available from: https://learningcenter.ehaweb.org/eha/2017/22nd/182689/monica.ziff.real.world.use.of.ixazomib.with.lenalidomide.and.dexamethasone.for.html
   Google Scholar
• Costello C, Davies FE, Cook G, et al. INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. Future Oncol. 2019;15(13):1411–1428.
   PubMed Web of Science ®Google Scholar
• Richardson PG, San Miguel JF, Moreau P, et al. Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018;8:109.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101(4):396–406.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–e548.
   PubMed Web of Science ®Google Scholar
• Health NI of Institute NCI. Common terminology criteria for adverse events (CTCAE) version 4.03 [Internet]; 2010. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Kumar SK, Dimopoulos MA, Kastritis E, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31(11):2443–2448.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Dispenzieri A, Chim CS, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269–277.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(7):719–734.
   PubMed Web of Science ®Google Scholar
• Mateos M, Masszi T, Grzasko N, et al. Impact of prior therapy on the efficacy and safety of oral ixazomib–lenalidomide–dexamethasone vs. placebo-lenalidomide–dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 2017;102(10):1767–1775.
   PubMed Web of Science ®Google Scholar
• Sonneveld P, Avet-Loiseau H, Lonial S, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127(24):2955–2962.
   PubMed Web of Science ®Google Scholar
• Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135–1141.
   PubMed Web of Science ®Google Scholar
• Avet-Loiseau H, Bahlis NJ, Chng WJ, et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood. 2017;130(24):2610–2618.
   PubMed Web of Science ®Google Scholar
• An G, Li Z, Tai YT, et al. The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015;21(9):2148–2156.
   PubMed Web of Science ®Google Scholar
• Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781–794.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Stewart AK, Masszi T, et al. Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017;7:1–9.
   Web of Science ®Google Scholar
• Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017;178(6):896–905.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Belch AR, White DJ, et al. Daratumumab, lenalidomide and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in RRMM based on prior lines and treatment exposure: POLLUX. Clin Lymphoma Myeloma Leuk. 2017;17(1):e116.
   Web of Science ®Google Scholar
• Bahlis NJ, Corso A, Mugge LO, et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia. 2017;31(11):2435–2442.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459–3466.
   PubMed Web of Science ®Google Scholar
• Hari P, Romanus D, Palumbo A, et al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed/refractory multiple myeloma in routine clinical care in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(2):152–160.
   PubMed Web of Science ®Google Scholar
• Yong K, Delforge M, Driessen C, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175(2):252–264.
   PubMed Web of Science ®Google Scholar